Human Leukocyte Antigen-G: A Promising Prognostic Marker of Disease Progression to Improve the Control of Human African Trypanosomiasis

Registro completo de metadados
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorGineau, Laure-
Autor(es): dc.creatorCourtin, David-
Autor(es): dc.creatorCamara, Mamadou-
Autor(es): dc.creatorIlboudo, Hamidou-
Autor(es): dc.creatorJamonneau, Vincent-
Autor(es): dc.creatorDias, Fabricio C.-
Autor(es): dc.creatorTokplonou, Leonidas-
Autor(es): dc.creatorMilet, Jacqueline-
Autor(es): dc.creatorMendonça, Priscila B.-
Autor(es): dc.creatorCastelli, Erick C.-
Autor(es): dc.creatorCamara, Oumou-
Autor(es): dc.creatorCamara, Mariam-
Autor(es): dc.creatorFavier, Benoit-
Autor(es): dc.creatorRouas-Freiss, Nathalie-
Autor(es): dc.creatorMoreau, Philippe-
Autor(es): dc.creatorDonadi, Eduardo A.-
Autor(es): dc.creatorBucheton, Bruno-
Autor(es): dc.creatorSabbagh, Audrey-
Autor(es): dc.creatorGarcia, André-
Data de aceite:
Data de disponibilização:
Data de envio:
Data de envio:
Data de envio:
Fonte completa do material: dc.identifier
Fonte completa do material: dc.identifier
Fonte: dc.identifier.uri
Descrição: dc.descriptionBackground. Human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambiense can be diagnosed in the early hemolymphatic stage (stage 1 [S1]) or meningoencephalitic stage (stage 2 [S2]). Importantly, individuals harbouring high and specific antibody responses to Tbg antigens but negative parasitology are also diagnosed in the field (seropositive [SERO]). Whereas some develop the disease in the months following their initial diagnosis (SERO/HAT), others remain parasitologically negative for long periods (SERO) and are apparently able to control infection. Human leucocyte antigen (HLA)-G, an immunosuppressive molecule, could play a critical role in this variability of progression between infection and disease. Methods. Soluble HLA-G (sHLA-G) was measured in plasma for patients in the SERO (n = 65), SERO/HAT (n = 14), or HAT (n = 268) group and in cerebrospinal fluid for patients in S1 (n = 55), early S2 (n = 93), or late S2 (n = 110). Associations between these different statuses and the soluble level or genetic polymorphisms of HLA-G were explored. Results. Plasma sHLA-G levels were significantly higher in HAT (P = 6 × 10-7) and SERO/HAT (P =. 007) than SERO patients. No difference was observed between the SERO/HAT and HAT groups. Within the HAT group, specific haplotypes (HG010102 and HG0103) displayed increased frequencies in S1 (P =. 013) and late S2 (P =. 036), respectively. Conclusions. These results strongly suggest the involvement of HLA-G in HAT disease progression. Importantly, high plasma sHLA-G levels in SERO patients could be predictive of subsequent disease development and could represent a serological marker to help guide therapeutic decision making. Further studies are necessary to assess the predictive nature of HLA-G and to estimate both sensitivity and specificity.-
Formato: dc.format1189-1197-
Idioma: dc.languageen-
Relação: dc.relationClinical Infectious Diseases-
Relação: dc.relation5,051-
Relação: dc.relation5,051-
Direitos: dc.rightsopenAccess-
Palavras-chave: dc.subjectgenetic association-
Palavras-chave: dc.subjectHLA-G-
Palavras-chave: dc.subjecthuman African trypanosomiasis-
Palavras-chave: dc.subjectsusceptibility-
Palavras-chave: dc.subjectTrypanosoma brucei gambiense-
Título: dc.titleHuman Leukocyte Antigen-G: A Promising Prognostic Marker of Disease Progression to Improve the Control of Human African Trypanosomiasis-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.